FTC Gives Go-Ahead To $725M Lab Testing Merger
The agency granted early termination to its antitrust review after the companies’ Oct. 6 announcement of Miraca’s plans to acquire the anatomic pathology business operated by Texas-based Caris Diagnostics Inc., a Caris subsidiary with specialties including gastrointestinal pathology and dermatopathology.
An attorney for Caris declined to comment Tuesday.
Miraca, Japan’s biggest clinical diagnostics and laboratory testing services...
To view the full article, register now.